DUO-E — Durvalumab Plus Carboplatin-Paclitaxel With or Without Olaparib in Advanced or Recurrent Endometrial Cancer (DUO-E)

Phase 3 · 2023 · Endometrial Cancer

Design

Randomized trial of carboplatin-paclitaxel plus placebo versus plus durvalumab (then durvalumab maintenance) versus plus durvalumab and olaparib (then durvalumab plus olaparib maintenance).

Population

Newly diagnosed advanced (stage III/IV) or recurrent endometrial cancer.

Primary Endpoint

progression-free survival (PFS)

Key Result

PFS improved with durvalumab (HR 0.71) and further with durvalumab plus olaparib (HR 0.55); dMMR tumors benefited most from immunotherapy while pMMR tumors gained from added olaparib.

Guideline Impact

NCCN-listed durvalumab plus chemotherapy (± olaparib) for advanced/recurrent endometrial cancer